Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salcol is a nutraceutical product developed and marketed by Amdis Healthsciences, primarily indicated for the management of joint pain and osteoarthritis. Its primary active ingredient is **undenatured collagen type II (UC-II)**, a protein derived from chicken sternum cartilage. Unlike denatured collagen, UC-II maintains its biological activity and works through a mechanism known as oral tolerance. Upon ingestion, it interacts with Peyer's patches in the gut-associated lymphoid tissue (GALT), triggering the production of regulatory T cells (Tregs) that migrate to the joints and release anti-inflammatory cytokines like IL-10 and TGF-beta. This process helps to suppress the immune-mediated destruction of articular cartilage and promotes joint repair and mobility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Salcol.